Shares of AEON Biopharma Inc. (AEON) are down over 55% at $1.49 in premarket trading Friday, following disappointing phase II trial results of ABP-450 in the preventive treatment for chronic migraine.
ABP-450, the company's lead candidate, is a 900-kDa botulinum toxin type A complex.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.